Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon L Croft

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 13, 2003
Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activityGunther Bal, Pieter Van der Veken, Dimitri Antonov, et al.
Plos Neglected Tropical Diseases|February 3, 2021
Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, IndiaNatalie J Dial, Graham F Medley, Simon L Croft, et al.
Journal of Inorganic Biochemistry|June 24, 2003
Transition metal complexes of buparvaquone as potent new antimalarial agents. 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against Plasmodium falciparumNikhil H Gokhale, Subhash B Padhye, Simon L Croft, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2018
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin BGert-Jan Wijnant, Katrien Van Bocxlaer, Amanda Fortes Francisco, et al.
International Journal of Antimicrobial Agents|May 30, 2017
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasisHollie Burrell-Saward, Andrew J Harris, Raul de LaFlor, et al.
The Lancet. Infectious Diseases|August 2, 2002
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agendaPhilippe J Guerin, Piero Olliaro, Shyam Sundar, et al.
Molecular and Biochemical Parasitology|June 28, 2005
Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenaseRebecca Conners, Felix Schambach, Jon Read, et al.
Natural Product Reports|December 16, 2021
Marine alkaloids as bioactive agents against protozoal neglected tropical diseases and malariaAndre G Tempone, Pauline Pieper, Samanta E T Borborema, et al.
Antimicrobial Agents and Chemotherapy|July 3, 2019
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous LeishmaniasisGert-Jan Wijnant, Simon L Croft, Raul de la Flor, et al.
Nature Medicine|January 11, 2011
Triclosan is minimally effective in rodent malaria modelsWerner Baschong, Sergio Wittlin, Kirstine A Inglis, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Bioorganic & Medicinal Chemistry Letters|November 13, 2003
Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activityGunther Bal, Pieter Van der Veken, Dimitri Antonov, et al.
Plos Neglected Tropical Diseases|February 3, 2021
Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, IndiaNatalie J Dial, Graham F Medley, Simon L Croft, et al.
Journal of Inorganic Biochemistry|June 24, 2003
Transition metal complexes of buparvaquone as potent new antimalarial agents. 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against Plasmodium falciparumNikhil H Gokhale, Subhash B Padhye, Simon L Croft, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2018
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin BGert-Jan Wijnant, Katrien Van Bocxlaer, Amanda Fortes Francisco, et al.
International Journal of Antimicrobial Agents|May 30, 2017
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasisHollie Burrell-Saward, Andrew J Harris, Raul de LaFlor, et al.
The Lancet. Infectious Diseases|August 2, 2002
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agendaPhilippe J Guerin, Piero Olliaro, Shyam Sundar, et al.
Molecular and Biochemical Parasitology|June 28, 2005
Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenaseRebecca Conners, Felix Schambach, Jon Read, et al.
Natural Product Reports|December 16, 2021
Marine alkaloids as bioactive agents against protozoal neglected tropical diseases and malariaAndre G Tempone, Pauline Pieper, Samanta E T Borborema, et al.
Antimicrobial Agents and Chemotherapy|July 3, 2019
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous LeishmaniasisGert-Jan Wijnant, Simon L Croft, Raul de la Flor, et al.
Nature Medicine|January 11, 2011
Triclosan is minimally effective in rodent malaria modelsWerner Baschong, Sergio Wittlin, Kirstine A Inglis, et al.
Pageof 15